CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
Vous n'êtes pas connecté
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
PASADENA, Calif.–(BUSINESS WIRE)–Sep. 2, 2024– Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 3 PALISADE...
FRIDAY, Aug. 30, 2024 -- Patients with early-onset colorectal cancer (EO-CRC) living in rural areas have lower five-year survival rates than their...
TUESDAY, Sept. 10, 2024 -- Omission of 5-fluorouracil (5-FU) from the first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens is not associated with...
BAYRY enrolls the first patient in the phase III SOHO-02 study among treatment-na??ve patients with advanced NSCLC with HER2-activating mutations.
LOS ALTOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing...
THURSDAY, Sept. 5, 2024 -- Lung function remains stable over three years after hematopoietic cell transplant (HCT) among patients with sickle cell...
MONDAY, Sept. 9, 2024 -- Cancer diagnosis is associated with an increased risk for psychological illness and cardiovascular disease among...